News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Save the Date: Egetis to host Investor Day on December 19, 2023

December 1, 2023

Stockholm, Sweden, December 1, 2023. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced that the Company will host an Investor Day on Tuesday December 19, 2023, in Stockholm, Sweden, for investors, analysts and media.
Time: Tuesday, December 19, 2023, at 3:00 pm – 6:00 pm CET (9:00 am – 12:00 pm ET)
Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden
The event will also be accessible through a live webcast.
During the event, the Company will provide an update and review of its strategy and pipeline. The presentations will focus on the unmet medical need, development plans, pre-launch activities and commercialization plans for the investigational drug Emcitate (tiratricol), being developed as a possible treatment for MCT8 deficiency, as well as additional activities to create and enhance long-term shareholder value.  Presentations will be made by members of Egetis’ management team and invited key opinion leaders.
A complete agenda and a link to the live webcast will be shared in advance of the event.
Presentations will be held in English.
If you would like to attend the event in person in Stockholm, please register by email to



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10